Neumora Therapeutics Business Summary

Neumora Therapeutics, Inc. (NMRA) is a clinical-stage biopharmaceutical company that operates on a pre-commercial business model, generating value through the development of a proprietary precision neuroscience platform rather than product sales. The company’s revenue potential is currently tied to future licensing agreements, milestone payments, and the eventual commercialization of its therapeutic pipeline, which is segmented into neuropsychiatry, neurodegeneration, and metabolic disorders. Neumora utilizes its Data Biopsy Signatures and Precision Phenotypes technologies to map brain disease heterogeneity, aiming to match targeted drug candidates like navacaprant (NMRA-140) and NMRA-215 to specific patient subpopulations. Within the competitive landscape, Neumora contends with established CNS-focused firms such as Sage Therapeutics, Jazz Pharmaceuticals, and Amylyx Pharmaceuticals, as well as precision-medicine peers like Wave Life Sciences. Neumora distinguishes itself by integrating large-scale data science with traditional drug discovery to address the high failure rates historically associated with central nervous system clinical trials. The company was founded by a high-pedigree team including Paul L. Berns, Kristina Burow, Robert Nelsen, Mike Poole, and Carol Suh, many of whom hail from ARCH Venture Partners. As of February 2026, the executive leadership team is led by Co-founder Paul L. Berns, who serves as Chairman and Chief Executive Officer, bringing extensive experience from his previous leadership at Anacor Pharmaceuticals. Supporting him are Joshua Pinto, Ph.D., as President, Michael Milligan as Chief Financial Officer, and Bill Aurora, Pharm.D., as Chief Operating and Development Officer. The company’s scientific strategy is overseen by Co-founder and Chief Scientific Officer Carol Suh. Neumora is backed by a formidable roster of institutional investors and strategic partners, including ARCH Venture Partners, Polaris Partners, Mubadala Investment Company, SoftBank Vision Fund 2, and Amgen, the latter of which entered into a significant strategic collaboration and equity investment to bolster Neumora’s precision medicine capabilities.